Cargando…

Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors

[Image: see text] Optimization of binding affinities for ligands to their target protein is a primary objective in rational drug discovery. Herein, we report on a collaborative study that evaluates various compounds designed to bind to the SET and MYND domain-containing protein 3 (SMYD3). SMYD3 is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Shunzhou, Bhati, Agastya P., Wright, David W., Wall, Ian D., Graves, Alan P., Green, Darren, Coveney, Peter V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131449/
https://www.ncbi.nlm.nih.gov/pubmed/35508076
http://dx.doi.org/10.1021/acs.jcim.2c00255
_version_ 1784713178039451648
author Wan, Shunzhou
Bhati, Agastya P.
Wright, David W.
Wall, Ian D.
Graves, Alan P.
Green, Darren
Coveney, Peter V.
author_facet Wan, Shunzhou
Bhati, Agastya P.
Wright, David W.
Wall, Ian D.
Graves, Alan P.
Green, Darren
Coveney, Peter V.
author_sort Wan, Shunzhou
collection PubMed
description [Image: see text] Optimization of binding affinities for ligands to their target protein is a primary objective in rational drug discovery. Herein, we report on a collaborative study that evaluates various compounds designed to bind to the SET and MYND domain-containing protein 3 (SMYD3). SMYD3 is a histone methyltransferase and plays an important role in transcriptional regulation in cell proliferation, cell cycle, and human carcinogenesis. Experimental measurements using the scintillation proximity assay show that the distributions of binding free energies from a large number of independent measurements exhibit non-normal properties. We use ESMACS (enhanced sampling of molecular dynamics with approximation of continuum solvent) and TIES (thermodynamic integration with enhanced sampling) protocols to predict the binding free energies and to provide a detailed chemical insight into the nature of ligand–protein binding. Our results show that the 1-trajectory ESMACS protocol works well for the set of ligands studied here. Although one unexplained outlier exists, we obtain excellent statistical ranking across the set of compounds from the ESMACS protocol and good agreement between calculations and experiments for the relative binding free energies from the TIES protocol. ESMACS and TIES are again found to be powerful protocols for the accurate comparison of the binding free energies.
format Online
Article
Text
id pubmed-9131449
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-91314492022-05-26 Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors Wan, Shunzhou Bhati, Agastya P. Wright, David W. Wall, Ian D. Graves, Alan P. Green, Darren Coveney, Peter V. J Chem Inf Model [Image: see text] Optimization of binding affinities for ligands to their target protein is a primary objective in rational drug discovery. Herein, we report on a collaborative study that evaluates various compounds designed to bind to the SET and MYND domain-containing protein 3 (SMYD3). SMYD3 is a histone methyltransferase and plays an important role in transcriptional regulation in cell proliferation, cell cycle, and human carcinogenesis. Experimental measurements using the scintillation proximity assay show that the distributions of binding free energies from a large number of independent measurements exhibit non-normal properties. We use ESMACS (enhanced sampling of molecular dynamics with approximation of continuum solvent) and TIES (thermodynamic integration with enhanced sampling) protocols to predict the binding free energies and to provide a detailed chemical insight into the nature of ligand–protein binding. Our results show that the 1-trajectory ESMACS protocol works well for the set of ligands studied here. Although one unexplained outlier exists, we obtain excellent statistical ranking across the set of compounds from the ESMACS protocol and good agreement between calculations and experiments for the relative binding free energies from the TIES protocol. ESMACS and TIES are again found to be powerful protocols for the accurate comparison of the binding free energies. American Chemical Society 2022-05-04 2022-05-23 /pmc/articles/PMC9131449/ /pubmed/35508076 http://dx.doi.org/10.1021/acs.jcim.2c00255 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by/4.0/Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Wan, Shunzhou
Bhati, Agastya P.
Wright, David W.
Wall, Ian D.
Graves, Alan P.
Green, Darren
Coveney, Peter V.
Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors
title Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors
title_full Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors
title_fullStr Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors
title_full_unstemmed Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors
title_short Ensemble Simulations and Experimental Free Energy Distributions: Evaluation and Characterization of Isoxazole Amides as SMYD3 Inhibitors
title_sort ensemble simulations and experimental free energy distributions: evaluation and characterization of isoxazole amides as smyd3 inhibitors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131449/
https://www.ncbi.nlm.nih.gov/pubmed/35508076
http://dx.doi.org/10.1021/acs.jcim.2c00255
work_keys_str_mv AT wanshunzhou ensemblesimulationsandexperimentalfreeenergydistributionsevaluationandcharacterizationofisoxazoleamidesassmyd3inhibitors
AT bhatiagastyap ensemblesimulationsandexperimentalfreeenergydistributionsevaluationandcharacterizationofisoxazoleamidesassmyd3inhibitors
AT wrightdavidw ensemblesimulationsandexperimentalfreeenergydistributionsevaluationandcharacterizationofisoxazoleamidesassmyd3inhibitors
AT walliand ensemblesimulationsandexperimentalfreeenergydistributionsevaluationandcharacterizationofisoxazoleamidesassmyd3inhibitors
AT gravesalanp ensemblesimulationsandexperimentalfreeenergydistributionsevaluationandcharacterizationofisoxazoleamidesassmyd3inhibitors
AT greendarren ensemblesimulationsandexperimentalfreeenergydistributionsevaluationandcharacterizationofisoxazoleamidesassmyd3inhibitors
AT coveneypeterv ensemblesimulationsandexperimentalfreeenergydistributionsevaluationandcharacterizationofisoxazoleamidesassmyd3inhibitors